BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsoriCell Gene Therapeutics
About this trial
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
Eligibility criteria
Qualifiers
Signed written informed consent; Patients volunteer to participate in the research
Diagnosis is mainly based on the World Health Organization (WHO) 2008
Patients have exhausted standard therapeutic options
Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks
Disqualifiers
Patients declining to consent for treatment
Prior solid organ transplantation
Potentially curative therapy including chemotherapy or hematopoietic cell transplant
Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents
Trial design
Treatments tested in this trial
- BCMA-CD19 cCAR T cells
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
iCell Gene Therapeutics
Lead sponsor
iCAR Bio Therapeutics Ltd.
Collaborator
Peking University Shenzhen Hospital
Collaborator
Source ClinicalTrials.gov